Literature DB >> 18666372

The diagnosis of drug-induced liver disease.

Pedro Zapater1, Rocío Moreu, José Francisco Horga.   

Abstract

The diagnosis of drug-induced liver injury is often one of exclusion with initial suspicion based on circumstantial evidence. The natural history, characteristics and limitations of this exclusion process are revised. Also, the numerous published attribution algorithms for evaluation of drug-related liver abnormalities are described and their characteristics and differences are illustrated with true patients from our clinical experience. Situations that complicate the diagnosis such as age, sex, concomitant use of other drugs, genetic polymorphism in metabolic pathways involved in activation or disposition of therapeutic drugs and drug-drug interactions are described. Finally, developing approach to diagnosis of drug-induced liver injury, different of attribution algorithms, are evaluated and explained using a new method based in a Bayesian approach developed and published by the authors. The authors' vision of all these potential advances and their clinical utility is provided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18666372     DOI: 10.2174/157488406776872514

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  3 in total

1.  The 21st century hepatologist and a systems biology based approach to liver diseases.

Authors:  Lopa Mishra
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

Review 2.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

3.  Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.

Authors:  Mohamed Kadry Taher; James A G Crispo; Yannick Fortin; Ryan Moog; Douglas McNair; Lise M Bjerre; Franco Momoli; Donald Mattison; Daniel Krewski
Journal:  J Gastroenterol Hepatol       Date:  2021-03-31       Impact factor: 4.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.